| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.DRUP.2004.03.002 |
| P698 | PubMed publication ID | 15158769 |
| P2093 | author name string | Rakesh K Srivastava | |
| Sharmila Shankar | |||
| P433 | issue | 2 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 139-156 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | Drug Resistance Updates | Q3040081 |
| P1476 | title | Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications | |
| P478 | volume | 7 |
| Q36681789 | (E)-2,4-bis(p-hydroxyphenyl)-2-butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK-mediated suppression of NF-κB and up-regulation of TNFRSF10B (DR5). |
| Q39527243 | 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells |
| Q36692259 | 5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related Proteins |
| Q81100364 | A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome |
| Q36670896 | AXL mediates TRAIL resistance in esophageal adenocarcinoma |
| Q37269047 | Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis |
| Q39845179 | Akt and 14-3-3 control a PACS-2 homeostatic switch that integrates membrane traffic with TRAIL-induced apoptosis |
| Q64990362 | Attenuation of autophagy flux by 6-shogaol sensitizes human liver cancer cells to TRAIL-induced apoptosis via p53 and ROS. |
| Q60958902 | Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL‑induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species |
| Q33915871 | BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced Apoptosis |
| Q39603958 | Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway |
| Q35915103 | Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy |
| Q54637021 | Characterization and expression analysis of TNF-related apoptosis inducing ligand (TRAIL) in grass carp Ctenopharyngodon idella. |
| Q39420757 | Chlorin-based photodynamic therapy enhances the effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in bladder cancer cells |
| Q46463388 | Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. |
| Q40007577 | Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway |
| Q41239989 | Combination of AAV-TRAIL with miR-221-Zip Therapeutic Strategy Overcomes the Resistance to TRAIL Induced Apoptosis in Liver Cancer |
| Q36151210 | Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis |
| Q36473635 | Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis |
| Q46575039 | Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). |
| Q40137255 | Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells |
| Q40105893 | Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells |
| Q38103591 | Death receptors as targets in cancer |
| Q35833213 | Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage |
| Q39583729 | Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. |
| Q51560838 | Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer. |
| Q35104391 | Effect of ALA-mediated photodynamic therapy in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on bladder cancer cells |
| Q37482834 | Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity |
| Q39209045 | Enhanced antitumor activity of the photosensitizer meso-Tetra(N-methyl-4-pyridyl) porphine tetra tosylate through encapsulation in antibody-targeted chitosan/alginate nanoparticles |
| Q39983073 | Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. |
| Q46118971 | Ethanolic extract of propolis (EEP) enhances the apoptosis- inducing potential of TRAIL in cancer cells |
| Q34028464 | Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy |
| Q47289111 | Glipizide sensitizes lung cancer cells to TRAIL-induced apoptosis via Akt/mTOR/autophagy pathways |
| Q104995052 | Glycosides from Vallaris solanaceae with TRAIL-Resistance-Overcoming Activity |
| Q39426125 | Gomisin N enhances TRAIL-induced apoptosis via reactive oxygen species-mediated up-regulation of death receptors 4 and 5 |
| Q41242816 | Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1. |
| Q54690940 | Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. |
| Q34803686 | In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas |
| Q34217464 | Induction of apoptosis coupled to endoplasmic reticulum stress in human prostate cancer cells by n-butylidenephthalide |
| Q39595646 | Isolation and structure elucidation of izuminosides A-C: a rare phenazine glycosides from Streptomyces sp. IFM 11260. |
| Q35954258 | Mechanisms of resistance to TRAIL-induced apoptosis in cancer |
| Q50866811 | Membrane expression of the death ligand trail receptors DR4 and DR5 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer. |
| Q50687736 | Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. |
| Q28307527 | Molecular targets of isothiocyanates in cancer: recent advances |
| Q83186138 | NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic |
| Q36285964 | On the TRAIL of a new therapy for leukemia. |
| Q40001770 | P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells |
| Q33991741 | Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis |
| Q34447588 | Prevention of bone growth defects, increased bone resorption and marrow adiposity with folinic acid in rats receiving long-term methotrexate |
| Q39748934 | Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. |
| Q36489164 | RRR-gamma-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling |
| Q39852248 | Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin |
| Q40073029 | Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. |
| Q33288897 | Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression |
| Q30994649 | Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor |
| Q42320898 | Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin |
| Q36791533 | Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. |
| Q37262987 | Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis. |
| Q55239517 | Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. |
| Q36059686 | Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential |
| Q35229797 | Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. |
| Q46781768 | Sharkquinone, a new ana-quinonoid tetracene derivative from marine-derived Streptomyces sp. EGY1 with TRAIL resistance-overcoming activity. |
| Q34202880 | Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression |
| Q39966860 | Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells |
| Q59807366 | Sulforaphane from Cruciferous Vegetables: Recent Advances to Improve Glioblastoma Treatment |
| Q35927476 | TRAIL and its receptors as targets for cancer therapy |
| Q36197395 | TRAIL and paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro. |
| Q83919556 | TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma |
| Q33802751 | TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro |
| Q36731174 | TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. |
| Q34564468 | TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. |
| Q37012681 | TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo |
| Q36832154 | Targeting death-inducing receptors in cancer therapy |
| Q35762274 | Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy |
| Q90746446 | The biological implications of Yin Yang 1 in the hallmarks of cancer |
| Q39654825 | The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines |
| Q36733723 | The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies |
| Q54463020 | The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. |
| Q36294675 | The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL |
| Q37178718 | Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. |
| Q83855426 | Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis |
| Q35082212 | Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation |
| Q39392684 | Yoropyrazone, a new naphthopyridazone alkaloid isolated from Streptomyces sp. IFM 11307 and evaluation of its TRAIL resistance-overcoming activity. |
| Q41920847 | microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis |
| Q39400925 | β-Phenethyl isothiocyanate induces death receptor 5 to induce apoptosis in human oral cancer cells via p38. |
Search more.